Oncogenes Stocks List

Recent Signals

Date Stock Signal Type
2021-04-09 ALRN 180 Bearish Setup Bearish Swing Setup
2021-04-09 ALRN Stochastic Reached Oversold Weakness
2021-04-09 ALRN Fell Below 200 DMA Bearish
2021-04-09 BDTX Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-04-09 BDTX 20 DMA Support Bullish
2021-04-09 BGNE Stochastic Reached Oversold Weakness
2021-04-09 BPTH Narrow Range Bar Range Contraction
2021-04-09 BPTH Spinning Top Other
2021-04-09 BPTH Stochastic Reached Oversold Weakness
2021-04-09 BPTH 1,2,3 Pullback Bullish Bullish Swing Setup
2021-04-09 BPTH Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-04-09 BPTH Calm After Storm Range Contraction
2021-04-09 CLLS Bollinger Band Squeeze Range Contraction
2021-04-09 CLLS Narrow Range Bar Range Contraction
2021-04-09 CLLS NR7 Range Contraction
2021-04-09 KURA Bollinger Band Squeeze Range Contraction
2021-04-09 KURA Hammer Candlestick Bullish
2021-04-09 KURA 20 DMA Support Bullish

Recent News for Oncogenes Stocks

Date Stock Title
Apr 10 BGNE The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight
Apr 10 BDTX Black Diamond Therapeutics Announces Preclinical Data Presentations on BDTX-189 and BDTX-1535 at American Association for Cancer Research Annual Meeting
Apr 9 BGNE Seeking Alpha Catalyst Watch
Apr 9 CLLS Cellectis finalizes of $47M through ATM program
Apr 9 CLLS Cellectis Completes Sale of $47 million through its ATM program
Apr 8 BGNE BeiGene's Zanubrutinib Fails To Meet Efficacy Endpoints In Mid-Stage COVID-19 Study
Apr 8 BGNE BeiGene's zanubrutinib fails to meet co-primary endpoints in COVID-19-related pulmonary distress
Apr 8 BGNE BeiGene Launches BRUKINSA® (Zanubrutinib) in Canada for Patients with Waldenström’s Macroglobulinemia
Apr 8 BGNE BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress
Apr 7 BGNE BeiGene Announces First Commercial Manufacturing Approval for Its State-of-the-Art Biologics Facility in Guangzhou, China
Apr 5 BPTH TSLA, NVTA, CHPT and NNOX among premarket gainers
Apr 5 BPTH Bio-Path Stock Is Trading Higher As Prexigebersen Triplet Combo Shows Favorable Safety Profile In Acute Myeloid Leukemia Study
Apr 5 BPTH Bio-Path shares rise after mid-stage leukemia trial update
Apr 5 BPTH Bio-Path Holdings Announces Successful Completion of Safety Cohort of Triple Combination of Prexigebersen, Decitabine and Venetoclax in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid Leukemia

An oncogene is a gene that has the potential to cause cancer. In tumor cells, they are often mutated or expressed at high levels.Most normal cells will undergo a programmed form of rapid cell death (apoptosis) when critical functions are altered and malfunctioning. Activated oncogenes can cause those cells designated for apoptosis to survive and proliferate instead. Most oncogenes began as proto-oncogenes, normal genes involved in cell growth and proliferation or inhibition of apoptosis. If normal genes promoting cellular growth, through mutation, are up-regulated, (gain of function mutation) they will predispose the cell to cancer and are thus termed oncogenes. Usually multiple oncogenes, along with mutated apoptotic or tumor suppressor genes will all act in concert to cause cancer. Since the 1970s, dozens of oncogenes have been identified in human cancer. Many cancer drugs target the proteins encoded by oncogenes.

More about Oncogenes
Browse All Tags